Through the application of both static and dynamic biomarkers, such as multiplex immunofluorescence to analyze tumor microenvironment (TME) characteristics, Next-Generation Sequencing (NGS), and evaluating of PD-1/PD-L1 expression on NK cells, we aim to identify patient populations with favorable prognoses. The gene discussed is PDCD1; the disease is neoplasm.